Finerenone with Empagliflozin in Chronic Kidney Disease and Type …
Jun 5, 2025 · Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, …
Tirzepatide as Compared with Semaglutide for the Treatment of …
May 11, 2025 · Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults …
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a …
Lepodisiran - The New England Journal of Medicine
Mar 30, 2025 · Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small …
Zongertinib in Previously Treated - The New England Journal of …
Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is …
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl …
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
May 15, 2025 · Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with …
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …
Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …
First-Line Camizestrant for Emerging - The New England Journal of …
Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) …
Sotatercept in Patients with Pulmonary Arterial Hypertension at …
Mar 31, 2025 · Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial …